Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | TOP2A | P11388 | 1/20 | 0.98 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL27326849 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29375999 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29742318 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL27585549 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10588295 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7247 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7248 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL418714 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7056079 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL2107916 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | INCYCLIX BIO, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250092469-A1 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | GANYMED PHARMACEUTICALS GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| CN-119177284-A | Methods and compositions for predicting therapeutic efficacy of cancer treatment and prognosis of cancer | 安斯泰来制药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240335533-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | GANYMED PHARMACEUTICALS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| CN-113406327-B | Diagnosis and treatment of cancer involving cancer stem cells | 生物技术公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116635054-A | Compounds comprising tetrapeptide moieties | 科比欧尔斯公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-109172820-B | Combination therapy involving antibodies directed against claudin 18.2 for the treatment of cancer | 加尼梅德药物公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-115282269-A | Combination therapy involving anti-claudin 18.2 antibodies for the treatment of cancer | 安斯泰来制药株式会社 | 2022-11-04 | — | — | CN | disclosed |
| CN-115177733-A | Combination therapy involving anti-claudin 18.2 antibodies for the treatment of cancer | 安斯泰来制药株式会社 | 2022-10-14 | — | — | CN | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
| US-6548071-B1 | Anticancer agent | PHARMACIA & UPJOHN COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-5932709-A | REACTING DISACCHARIDE WITH PROTECTING REAGENT, REACTING PRODUCT WITH HALOGENATING AGENT, REACTING WITH REDUCING AGENT TO FORM DISACCHARIDE GLYCAL | UNIVERSITY OF MICHIGAN (US) | 1999-08-03 | — | — | US | disclosed |
| US-5677286-A | ANTICANCER AGENTS | THE UNIVERSITY OF MICHIGAN (US) | 1997-10-14 | — | — | US | disclosed |
| CN-1035380-C | Water soluble camptothecin analogs | SMITHKLINE BEECHAM CORP (US) | 1997-07-09 | — | — | CN | disclosed |
| WO-1996034003-A1 | GLYCOSYLATED ANALOGS OF CAMPTOTHECIN | UNIVERSITY OF MICHIGAN (US) | 1996-10-31 | — | — | WO | disclosed |
| CN-1027265-C | Process for preparing water soluble camptothecin analogs | SMITHKLINE BECKMAN CORP (US) | 1995-01-04 | — | — | CN | disclosed |
| CN-1087637-A | The preparation method of water soluble camptothecin analogs | SMITHKLINE BEECHAM CORP (US) | 1994-06-08 | — | — | CN | disclosed |
| CN-1083817-A | Water soluble camptothecin analogs | SMITHKLINE BECKMAN CORP (US) | 1994-03-16 | — | — | CN | disclosed |
| CN-1034724-A | WATER SOLUBLE CAMPTOTHECIN ANALOGS | SMITHKLINE BECKMAN CORP (US) | 1989-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092469-A1 | METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND CANCER PROGNOSIS | TP53, MKI67, TSG101 | TOP1 138/4885MEN1 2987/4885KMT2A 3412/4885 |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | TOP1 217/4885MEN1 916/4885KMT2A 1349/4885 |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | CDK2, CDK6, CDK4 | TOP1 620/4885MEN1 978/4885KMT2A 520/4885 |
| US-20240335533-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | EPCAM, KRT18, CALU | TOP1 155/4885MEN1 1562/4885KMT2A 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.